New Delhi: The results of Sputnik for 20,000 people shows that its efficacy cuts across age groups and co-morbidities, Mr. Sapra said. For the 60-plus age group, the vaccine showed an efficacy of 91.8 per cent, which proves its consistency, he added.
New Delhi: Russian-made Coronavirus vaccine Sputnik — peer-reviewed by the Lancet Medical Journal — is undergoing trials in India and could be available for use soon. “I believe the vaccine should be available in India from March- April,” Deepak Sapra, the chief of API and pharma services at Dr Reddy’s Laboratories, which is manufacturing the vaccine, told NDTV. Currently two vaccines — Serum Institute’s Covishield and Bharat Biotech’s Covaxin — are being administered to three crore health workers and frontline workers like the police and sanitation workers.
How to expand the intellectual landscape in Pakistan
Family background significantly influences academic and professional trajectories in Pakistan. The underrepresentation of individuals from lower socio-economic backgrounds in academia,...
Read more
